Antidepressant-induced jitteriness/anxiety syndrome: systematic
                        review

Sinclair, Lindsey I; Christmas, David; Hood, Sean; Potokar, John; Robertson, Andrea; Isaac, Andrew; Srivastava, Shrikant; Nutt, David; Davies, Simon

doi:10.1192/bjp.bp.107.048371

Cited by 153 publications

(108 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings corroborate clinical observations showing that selective serotonin reuptake and selective serotonin and norepinephrine reuptake inhibitors cause anxiety states in the early stages of treatment [34]. Indeed, a single dose ofcitalopram has been found to increase both the alarm reaction [35] and anxiety in healthy volunteers [36].…”

Section: Discussionsupporting

confidence: 88%

Psychopharmacological Profile of Ascorbate in aged Wistar Rats

RostirolaElsner¹,

Moysés²,

Bertoldi³

et al. 2017

J Syst Integr Neurosci

View full text Add to dashboard Cite

Clinical and preclinical findings have suggested a role for ascorbate in mood disorders. The present study was designed to investigate the effect of acute and chronic ascorbate treatment in animal models of memory, anxiety and depression using discriminative avoidance, forced swimming, light-dark box and openfield tests. Aged male Wistar rats (18 months) were treated with saline or ascorbate (50, 500 or 1000 mg/kg body weight) during 25 days. The acute treatment did not improve learning and memory parameters evaluated in the plus maze discriminative avoidance test. Besides, in the training session, ascorbate (1000 mg/kg) decreased the time spent in the open arms and 500 and 1000 mg/kg doses increased the time spent in the nonaversive enclosed arm, indicating anxiety-like behavior. On the 10 th day of treatment, ascorbate (1000 mg/kg) showed an antidepressant-like activity, since the treated animals showed decreased immobility time when compared to the saline group in the forced swimming test. The treatment with ascorbate did not alter any parameters in the light-dark box test evaluated on the 15 th day; however, on the 25 th day, ascorbate (500 mg/kg and 1000 mg/kg) decreased the number of entries into peripheral squares and the number of rearings in the open field test, suggesting an anxiolytic-like profile. In conclusion, our findings suggest that acute ascorbate treatment may induces an anxiety state, while at long term seems to exert anxiolytic activity, as well as exhibiting an antidepressant-like activity in aged rats.

show abstract

Section: Discussionsupporting

confidence: 88%

Psychopharmacological Profile of Ascorbate in aged Wistar Rats

RostirolaElsner¹,

Moysés²,

Bertoldi³

et al. 2017

J Syst Integr Neurosci

View full text Add to dashboard Cite

show abstract

“…21 We obtained terms for other potential precursors to suicidality and violence from the literature. 16,22,23 A systematic review has shown a lack of consensus about what the symptoms of activation are, 22 and we were uncertain about whether some events (e.g., nightmares, which can be a prelude to a psychotic event) should be treated as psychotic events. 24 We therefore consulted a professor in psychiatry.…”

Section: Search Termsmentioning

confidence: 99%

Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports

Maund

Guski

Gøtzsche

2016

CMAJ

View full text Add to dashboard Cite

The European Medicines Agency makes clinical study reports publicly available and publishes reasons for not approving applications for marketing authorization. Duloxe tine has been approved in Europe for the treatment of stress urinary incontinence in women. The reported adverse effects of duloxe tine include mental health problems and suicidality. We obtained clinical study reports from the European Medicines Agency concerning use of this drug for stress urinary incontinence.

show abstract

“…However SSRIs have potentially troublesome adverse effects, including initial increased nervousness, insomnia, nausea and sexual dysfunction [I (M)] (Gartlehner et al, 2011;Serretti and Chiesa, 2009;Sinclair et al, 2009). …”

Section: Ssris and Snrismentioning

confidence: 99%

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

et al. 2014

View full text Add to dashboard Cite

This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees.

show abstract

Antidepressant-induced jitteriness/anxiety syndrome: systematic review

Cited by 153 publications

References 38 publications

Psychopharmacological Profile of Ascorbate in aged Wistar Rats

Psychopharmacological Profile of Ascorbate in aged Wistar Rats

Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Contact Info

Product

Resources

About